Basic Information
Kartos Therapeutics is a clinical-stage biopharmaceutical company focused on developing the MDM2 inhibitor KRT-232. The company is committed to developing novel targeted therapies to meaningfully improve the lives of cancer patients.
Kartos Therapeutics, Inc.
California,United States of America
15~50 people
January 01, 2018
info@kartosthera.com